ClinicalTrials.gg

Program

Crizotinib

Also written as “crizotinib”, “PF-02341066” and “Crizotinib plus sunitinib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uveal Melanoma · Neoplasms · Lymphoma · Lymphoma, Large-Cell, Anaplastic, led by 3 companies.

Furthest: phase 4, since Jul 19, 201831 company-led studies, 2 open or runningNext primary completion: Mar 21, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer291 open or runningphase 4since Jul 19, 2018Dec 29, 2007Mar 21, 2028phase 4 · NCT05160922
Hoffmann-La Roche10 open or runningphase 3since Jun 20, 2017Jun 20, 2017none ahead
IDEAYA Biosciences11 open or runningphase 3since Aug 21, 2026Aug 21, 2026Mar 2034phase 3 · NCT07804186

Also a collaborator on its studies: Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 17 studies since Dec 29, 2007.

  1. Dec 22, 2011Phase 2 study in Carcinoma, Non-Small-Cell LungPfizer · NCT01500824
  2. Feb 25, 2012Phase 1 study in HealthyPfizer · NCT01549574 · 16 enrolled · Belgium
  3. Mar 30, 2012Phase 1 study in Advanced CancerPfizer · NCT01576406 · 88 enrolled · United States
  4. Jul 10, 2012Phase 3 study in Carcinoma, Non-Small-Cell LungPfizer · NCT01639001 · 207 enrolled · China, Hong Kong, Malaysia and more
  5. Sep 5, 2013Phase 2 study in Carcinoma, Non-Small-Cell LungPfizer · NCT01945021 · 129 enrolled · China, Japan, Korea, Republic of and more
  6. Nov 26, 2013Phase 1 study in CarcinomaPfizer · NCT01999972 · 50 enrolled · United States, United Kingdom
  7. Dec 5, 2013Phase 1 study in HealthyPfizer · NCT02006277 · 21 enrolled · Belgium
  8. Jul 22, 2015Phase 1 study in Lung NeoplasmsPfizer · NCT02511184 · 9 enrolled · United States
  9. Apr 26, 2017Phase 1 study in HealthyPfizer · NCT03137134 · 18 enrolled · United States
  10. Jun 20, 2017Hoffmann-La Roche's first study: phase 3 study in NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT03194893 · 50 enrolled · United States, France, Hong Kong and more
  11. Jul 19, 2018Phase 4 study in ALK or ROS1-positive NSCLCPfizer · NCT03672643 · 41 enrolled · China
  12. Apr 20, 2021Phase 1 study in Healthy ParticipantsPfizer · NCT04856293 · 25 enrolled · United States
  13. Dec 6, 2021Phase 4 study in Carcinoma, Non-Small-Cell LungPfizer · NCT05160922 · 27 enrolled · China, Italy, Japan and more
  14. Aug 21, 2026IDEAYA Biosciences's first study: phase 3 study in Uveal MelanomaNew to IDEAYA BiosciencesIDEAYA Biosciences · NCT07804186 · 450 planned · United States, Australia, Canada and more

Ahead

  1. Mar 21, 2028Primary completion: phase 4 study in Carcinoma, Non-Small-Cell LungPfizer · NCT05160922
  2. Mar 2034Primary completion: phase 3 study in Uveal MelanomaIDEAYA Biosciences · NCT07804186

TargetBeta

“An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity”NCIt, by rule
“Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor”ChEMBL 37, by rule

Studies

All 31 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07804186Uveal Melanoma · United States, Australia, Canada and more3RecruitingIDEAYA BiosciencesMar 2034450
NCT05160922Carcinoma, Non-Small-Cell Lung · China, Italy, Japan and more4Active, not recruitingPfizerMar 21, 202827
NCT04856293Healthy Participants · United States1CompletedPfizerDec 15, 202125
NCT03672643ALK or ROS1-positive NSCLC · China4TerminatedPfizerSep 28, 202341
NCT03194893Neoplasms · United States, France, Hong Kong and more3CompletedHoffmann-La RocheSep 18, 202550
NCT03137134Healthy · United States1CompletedPfizerSep 19, 201718
NCT02511184Lung Neoplasms · United States1TerminatedPfizerDec 20179
NCT02006277Healthy · Belgium1CompletedPfizerMar 201421
NCT01999972Carcinoma · United States, United Kingdom1CompletedPfizerFeb 22, 201750
NCT01945021Carcinoma, Non-Small-Cell Lung · China, Japan, Korea, Republic of and more2CompletedPfizerJul 31, 2015129
NCT01639001Carcinoma, Non-Small-Cell Lung · China, Hong Kong, Malaysia and more3CompletedPfizerJun 30, 2015207
NCT01576406Advanced Cancer · United States1CompletedPfizerJun 201688
NCT01549574Healthy · Belgium1CompletedPfizerMay 201216
NCT01500824Carcinoma, Non-Small-Cell Lung2WithdrawnPfizerMay 20160
NCT01441388Carcinoma, Renal Cell1WithdrawnPfizerNov 20130
NCT01419041Renal Insufficiency · United States1CompletedPfizerAug 201216
NCT01297595Healthy · Belgium1CompletedPfizerApr 201122
NCT01250730Healthy · Japan1CompletedPfizerJan 201118
NCT01168934Healthy · Belgium1CompletedPfizerSep 201014
NCT01154218Healthy · Belgium1CompletedPfizerNov 201036
NCT01149785Healthy · United States1CompletedPfizerSep 201015
NCT01147055Healthy · United States1CompletedPfizerOct 201015
NCT01125904Healthy · United States1CompletedPfizerJun 20105
NCT01121588Neoplasms · United States, China, Italy and more1TerminatedPfizerSep 7, 202344
NCT01121575Carcinoma, Non-Small-Cell Lung · United States, Australia1CompletedPfizerFeb 201470
NCT01082380Healthy Volunteer · United States1CompletedPfizerApr 20106
NCT00965731Carcinoma, Non-Small-Cell Lung · United States1CompletedPfizerDec 201127
NCT00939731Healthy · United States1CompletedPfizerAug 200924
NCT00932893Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more3CompletedPfizerMar 2012347
NCT00932451Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more2CompletedPfizerMar 20151,069
NCT00585195Lymphoma, Large-Cell, Anaplastic · United States, Australia, Japan and more1CompletedPfizerJul 30, 2020596

How it is read

Names in the registry

  • “crizotinib”, 21 entries
  • “PF-02341066”, 12 entries
  • “Crizotinib”, 11 entries
  • “Crizotinib plus sunitinib”, 2 entries
  • “Crizotinib (Xalkori)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.